



**STROKE**

**TBI**

**DEMENTIA**

## Early recovery with Cerebrolysin

Effective pharmacological treatment for  
**STROKE** patients

Muresanu D.F. et al., **Cerebrolysin And Recovery after Stroke (CARS)**,  
Stroke 2016; 47:151-159

### CARS results - Cerebrolysin in patients after STROKE

- Improvement of motor functions
- Early recovery
- Regain full independence
- Increase quality of life

**Cerebrolysin**<sup>®</sup>

Reconnecting Neurons.  
Empowering for Life.

# Cerebrolysin treatment facilitates early recovery

## Early therapeutic success after 14 days with Cerebrolysin

→ Patients are less dependent on caregivers early on

→ Strong decline in patient's post-stroke depression<sup>1</sup>




Figure: Treatment effects (Mann-Whitney) in the ARAT\* score

- **Superiority** of Cerebrolysin already after 14 days
- **Large treatment effect** at day 90 – **significant recovery**
- Fast and long-term effects in the Cerebrolysin group



full article

Published in  
**Stroke**

Stroke. January 2016;47:151-159  
Muresanu D.F. et al.

**Titel** Cerebrolysin And Recovery after Stroke (CARS) – A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

**Patients** **104 Cerebrolysin group + 104 Placebo group = 208 patients in total**  
Cerebrolysin group = Cerebrolysin + Standard rehabilitation therapy  
Placebo group = Saline + Standard rehabilitation therapy

**Treatment** **30ml/day for 21 days** followed by 69 days treatment-free period  
Primary endpoint = ARAT\* score on day 90

<sup>1</sup> J Rehabil Med. 2008;40:609-614, \* ARAT = Action Research Arm Test

ABBREVIATED PRESCRIBING INFORMATION. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer's type - Post-apoplectic complications - Craniocerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.